Polaryx Therapeutics IncPLYX
Price$2.02

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Net Income -$6.8MTTM through 30 Jun 2026
Free Cash Flow -$5.8MTTM through 30 Jun 2026

Margins

Current

Returns

-62.6%ROE
-58.0%ROA

Balance Sheet Health

Current Ratio13.53x
Cash & Equivalents$11.5M

Quality Metrics

Piotroski F-Score3 / 9
Earnings-Beat Rate0.0%

Multi-Year Trend

Diluted EPS-$0.14TTM
'24'25
FY2025: $-0.20

Dividend

No dividend

Capital Allocation

R&D Spend$2.5M

Segment Performance

SegmentRevenueYoYOutlook
Lysosomal Storage Disorders$00.0%
View details

Preparing to launch the SOTERIA Phase 2 proof-of-concept basket trial for PLX-200 across multiple lysosomal storage disorders.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.